Cite

HARVARD Citation

    Eriksen, J. et al. (n.d.). OC-009: Update of the randomised phase III trial DAHANCA 19: Primary C-RT or RT and zalutumumab for squamous cell carcinomas of head and neck. Radiotherapy and oncology. pp. 10-. [Online]. 
  
Back to record